Various STING agonists have been developed and tested in preclinical and clinical settings to treat cancers by activating the STING pathway.[30] In macrophages, the STING pathway can be activated by cytosolic dsDNA stimulation, particularly DNA longer than 70 bp.[31] In our study, it was evident that bacterial DNA could be released into the TME during bacteria‐mediated PTT. This evidence concerns the gene STING1 and cancer.